Form 4: Bolt Biotherapeutics Executive Grant Yonehiro Acquires 235,000 Stock Options
SEC Form 4 Filing
Grant Yonehiro, Chief Business Officer of Bolt Biotherapeutics, acquired 235,000 stock options on March 4, 2024, at an exercise price of $1.27.
Summary
- Grant Yonehiro, the Chief Business Officer of Bolt Biotherapeutics, filed a Form 4 on March 6, 2024, reporting a transaction.
- On March 4, 2024, Yonehiro acquired 235,000 stock options with an exercise price of $1.27.
- The options vest monthly, with 1/36th of the shares vesting for each month of continuous service following January 1, 2024.
- The options expire on March 3, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard executive compensation disclosure.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects to shareholders.
- The vesting schedule incentivizes the executive to remain with the company.
Key Dates
| Date | Description |
|---|---|
| January 1, 2024 | Start date for monthly vesting of stock options. |
| March 3, 2034 | Expiration date of the stock options. |
| March 4, 2024 | Date of the transaction: acquisition of stock options. |
| March 6, 2024 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.